Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis*
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective: Sepsis is a leading cause of mortality in noncoronary ICUs. Although immediate start of antibiotics reduces sepsis-related mortality, antibiotics are often administered for too long, leading to suboptimal treatment and, importantly, contributes to antimicrobial resistance. Prior literature suggests that procalcitonin correlates with infection and thus may help to guide the decision on when to stop antibiotic treatment. This study was conducted as part of a regulatory submission to the U.S. Food and Drug Administration and aimed to summarize the evidence of procalcitonin guidance on efficacy and safety outcomes in adult patients with sepsis. Data Sources: PubMed and the Cochrane Database of Systematic Reviews. Study Selection: English-language randomized controlled trials evaluating procalcitonin use among adult patients with suspected or confirmed sepsis published between January 2004 and May 2016. Data Extraction: Inverse-variance weighting fixed and random effects meta-analyses were performed on the following efficacy and safety endpoints: antibiotic duration, all-cause mortality, and length of ICU stay. Two reviewers independently extracted data elements from identified studies and measured risk of bias with the Cochrane Risk of Bias Tool. Data Synthesis: From a total of 369 potentially eligible articles, 10 randomized controlled trials containing 3,489 patients were used for analysis. Procalcitonin-guided patients had shorter antibiotics duration compared with controls (7.35 vs. 8.85 d; weighted mean difference, –1.49 d; 95% CI, –2.27 to –0.71; p < 0.001). Procalcitonin use had no adverse impact on mortality (risk ratio, 0.90; 95% CI, 0.79–1.03; p = 0.114) and length of ICU stay (11.09 d vs. 11.91 d; weighted mean difference, –0.84 d; 95% CI, –2.52 to 0.84; p = 0.329). Conclusions: In adult patients with suspected or confirmed sepsis, procalcitonin guidance reduces antibiotics duration with no observed adverse effects on patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 2×
“Although the methods employed to transform those variables were validated approaches and are expected to have affected both treatment arms similarly (18, 19), these methods created outliers for AB duration and ICU LOS and increased heterogeneity for these outcomes.”
Methodde Jong, E., van Oers, J. A., Beishuizen, A., Vos, P., Vermeijden, W. J., Haas, L. E., Loef, B. G., Dormans, T., van Melsen, G. C., Kluiters, Y. C., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00053-0 · Cited by 836
Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007
Lagu, T., Rothberg, M. B., Shieh, M.-S., Pekow, P. S., Steingrub, J. S., & Lindenauer, P. K. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318232db65 · Cited by 679
Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic Patients
Nobre, V., Harbarth, S., Graf, J.-D., Rohner, P., & Pugin, J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1238oc · Cited by 605 · cited 6×
“For ICU LOS, heterogeneity can be explained by the study by Nobre et al (31), which shows a 19-day reduction in ICU LOS.”
BackgroundMethodResultInfluentialJensen, J. U., Hein, L., Lundgren, B., Bestle, M. H., Mohr, T. T., Andersen, M. H., Thornberg, K. J., Løken, J., Steensen, M., Fox, Z., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31821e8791 · Cited by 356
Hochreiter, M., Köhler, T., Schweiger, A. M., Keck, F. S., Bein, B., von Spiegel, T., & Schroeder, S. (2009) · Critical Care · doi:10.1186/cc7903 · Cited by 315 · cited 4×
“The time horizon for mortality varied between studies: while four studies reported mortality during the patient’s stay in the ICU (24, 27, 29, 33), three studies reported mortality during the patient’s hospital stay (28, 30, 32), and three studies reported 28-day mortality (25, 26, 31).”
BackgroundInfluentialSchroeder, S., Hochreiter, M., Koehler, T., Schweiger, A.-M., Bein, B., Keck, F. S., & von Spiegel, T. (2009) · Langenbeck's Archives of Surgery · doi:10.1007/s00423-008-0432-1 · Cited by 238 · cited 4×
“The time horizon for mortality varied between studies: while four studies reported mortality during the patient’s stay in the ICU (24, 27, 29, 33), three studies reported mortality during the patient’s hospital stay (28, 30, 32), and three studies reported 28-day mortality (25, 26, 31).”
BackgroundInfluentialProcalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients.
Layios, N., Lambermont, B., Canivet, J.-L., Morimont, P., Preiser, J.-C., Garweg, C., Ledoux, D., Frippiat, F., Piret, S., Giot, J.-B., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318251517a · Cited by 137 · cited 7×
“Layios et al (29) Time until ICU discharge 258 251 < 0.”
BackgroundInfluentialAnnane, D., Maxime, V., Faller, J. P., Mezher, C., Clec'h, C., Martel, P., Gonzales, H., Feissel, M., Cohen, Y., Capellier, G., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002186 · Cited by 94 · cited 7×
“For example, while the study by Annane et al (24) included patients presenting with a “phenotype of severe sepsis or septic shock”, the study by Deliberato et al (27) only included patients with microbiologically confirmed infections.”
BackgroundResultInfluential
Cited by
Wirz, Y., Meier, M. A., Bouadma, L., Luyt, C. E., Wolff, M., Chastre, J., Tubach, F., Schroeder, S., Nobre, V., Annane, D., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2125-7 · Cited by 265
Self-citationTabah, A., Bassetti, M., Kollef, M. H., Zahar, J.-R., Paiva, J.-A., Timsit, J.-F., Roberts, J. A., Schouten, J., Giamarellou, H., Rello, J., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05866-w · Cited by 191
Peng, F., Chang, W., Xie, J.-F., Sun, Q., Qiu, H.-B., & Yang, Y. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.05.034 · Cited by 49
Arulkumaran, N., Khpal, M., Tam, K., Baheerathan, A., Corredor, C., & Singer, M. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004267 · Cited by 36
Metadata
- Authors
- Iankova, I., Thompson-Leduc, P., Kirson, N. Y., Rice, B., Hey, J., Krause, A., Schonfeld, S. A., DeBrase, C. R., Bozzette, S., & Schuetz, P.
- Venue
- Critical Care Medicine
- Published
- 2018-05
- Volume
- 46
- Issue
- 5
- Pages
- 691-698
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2780710346
- Cited by
- 106
- References
- 11
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis*. https://app.cochat.ai/papers/10.1097/ccm.0000000000002928
- The paper
- Iankova, I., Thompson-Leduc, P., Kirson, N. Y., Rice, B., Hey, J., Krause, A., Schonfeld, S. A., DeBrase, C. R., Bozzette, S., & Schuetz, P. (2018). Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis*. Critical Care Medicine. https://doi.org/10.1097/ccm.0000000000002928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.